<DOC>
	<DOCNO>NCT01171937</DOCNO>
	<brief_summary>The propose study attempt deepen understand repetitive behavior autism spectrum disorder ( ASD ) treatment examine change key neural circuit associate risperidone treatment use functional MRI . This study substudy large center grant ( IRB # 07-03-066 ) . Other study also center grant , include : IRB # 03-02-085 , IRB # 95-01-028 . All participant option enter another sub-study , meet criterion . The propose study address aim mount control trial 52 child Autism Spectrum Disorder . After screen assessment , child enter three-part study . Phase 1 8-week , double-blind , placebo-controlled flexible dose trial risperidone . The extension phase 16-week open-label maintenance phase responder risperidone placebo . Non-responders placebo invite enroll eight-week open-label study . 48 participant also undergo fMRI Week 8 blind treatment , optional sub-study . The medication dispense liquid suspension dose range 0.5 mg 4.0mg .</brief_summary>
	<brief_title>Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Male female race ethnicity age 8 16 year , 2 . Body weight great 20 kg body weight 3 . DSMIV diagnosis Autistic Disorder , PDD , NOS , Asperger 's Disorder ( establish clinical assessment , corroborate standard cutoff score Autism Diagnostic Interview Autism Diagnostic Observation Schedule ) , determine ADIR administer raters train research reliability , confirm experienced reliable clinician use DSMIVTR criterion . 4 . Anticonvulsants use treatment seizure disorder permit dosage stable 4 week patient seizure free least 6 month , 5 . Clinical Global Impression ( CGI ) Severity score least 4 ; subject must also score great 7 first 3 item Compulsions Subscale Revised PDD CYBOCS . 6 . Ambulatory status ( outpatient daytreatment ) time randomization 7 . Subject must demonstrate mental age &gt; 18 month determine Vineland Adaptive Behavior Scales . 8 . Subjects must free neuroleptic two week prior baseline . Subjects SSRIs stimulant , must stable dose least 4 week prior baseline visit . 9 . Subjects parent ( guardian ) must judge reliable medication compliance must agree keep appointment study visit test outline protocol . 1 . IQ mental age 18 month measure either ageappropriate form Wechsler , Revised Leiter , Mullen 2 . Females positive Beta HCG pregnancy test , 3 . Evidence prior adequate trial risperidone ( define duration four week dose least 2 mg per day ) 4 . Evidence hypersensitivity risperidone ( define allergic response [ e.g. , skin rash ] ) potentially serious adverse effect ( e.g. , significant tachycardia ) 5 . Past history neuroleptic malignant syndrome . 6 . DSMIV diagnosis substance abuse . 7 . A significant medical condition heart disease , hypertension , liver renal failure , pulmonary disease , unstable seizure disorder identify history , physical examination laboratory test . 8 . The use psychotropic medication</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>age 8-16</keyword>
	<keyword>Repetitive Behaviors</keyword>
</DOC>